Dr. Lin on CAR T-Cell Therapy–Related Toxicities in Multiple Myeloma
Yi Lin, MD, PhD, discusses CAR T-cell therapy–related toxicities in multiple myeloma.
Dr. Lin on Patient Characteristics From the CRB-401 Study of Ide-Cel in Myeloma
Yi Lin, MD, PhD, discusses the characteristics of patients who were included in the CRB-401 study examining the CAR T-cell product idecabtagene vicleucel in multiple myeloma.
Dr. Lin on the Promise of Cilta-Cel and Ide-Cel in Myeloma
Yi Lin, MD, PhD, discusses the promise of the CAR T-cell products ciltacabtagene autoleucel and idecabtagene vicleucel in patients with myeloma.
2 Clarke Drive Cranbury, NJ 08512